Description: GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Home Page: www.gsk.com
980 Great West Road
Brentford,
TW8 9GS
United Kingdom
Phone:
44 20 8047 5000
Officers
| Name | Title |
|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director |
| Ms. Julie Belita Brown A.C.A. | CFO & Executive Director |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D |
| Ms. Sarah Elton-Farr | Head of Investor Relations |
| Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance |
| Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office |
| Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development |
| Ms. Diana Conrad | Chief People Officer |
| Mr. Philip C. Thomson | President of Global Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 7.874 |
|---|---|
| Trailing PE: | 22.4726 |
| Price-to-Book MRQ: | 3.9648 |
| Price-to-Sales TTM: | 2.1379 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 70212 |